Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

BioNTech CEO says vaccine likely to protect against severe COVID from Omicron

11/30/2021 | 11:58am EST

* Established vaccine will likely prevent hospitalisation -CEO

* If needed, BioNTech ready to relaunch vaccine in 100 days

* CEO says he's worried by non-vaccinated, not so much by Omicron

FRANKFURT, Nov 30 (Reuters) - BioNTech and Pfizer's COVID-19 vaccine will likely offer strong protection against any severe disease from the new Omicron virus variant, BioNTech's Chief Executive told Reuters, as the firm weighs the need to upgrade its commonly used shot.

Lab tests are underway over the next two weeks to analyse the blood of people who had two or three doses of BioNTech's Comirnaty vaccine to see if antibodies found in that blood inactivate Omicron, shedding light on whether new vaccines are needed.

"We think it's likely that people will have substantial protection against severe disease caused by Omicron," said BioNTech CEO and co-founder Ugur Sahin. He specified severe disease as requiring hospital or intensive care.

Sahin added he expects the lab tests to show some loss of vaccine protection against mild and moderate disease due to Omicron, but the extent of that loss was hard to predict.

The biotech firm is speedily working on an upgraded version of its vaccine, of which well over 2 billion doses have been delivered, although it remains unclear whether that is needed, he added.

Sahin said getting a third vaccine shot known as a booster will likely confer a layer of protection against Omicron infections of any severity compared to those with just a two-shot course.

"To my mind there's no reason to be particularly worried. The only thing that worries me at the moment is the fact that there are people that have not been vaccinated at all," Sahin added.

BioNTech's guarded confidence contrasts with a sense of alarm conveyed by the chief executive of rival vaccine maker Moderna, Stephane Bancel, who has raised the prospect of a material drop in protection against the new coronavirus lineage from current vaccines.

Sahin said antibodies brought about by vaccination could struggle latching on to the new virus lineage but he added that t-cells, another line of immune defence, were set to recognise the vast parts of Omicron's spike protein that remain unchanged.

While antibodies bind to viruses directly and prevent infections, longer lasting t-cells attack cells that have already been hijacked by the virus, warding off viral replication and severe disease.

Pfizer and BioNTech have already created versions of their established mRNA-based vaccine - based on the original virus found in China - to target the so-called Alpha and Delta variants, with clinical trials continuing.

Those efforts are not meant to yield commercial products but to establish a routine with regulators that will help speed up any future vaccine relaunch.

Sahin said that was why regulators would unlikely require testing on human volunteers and an analysis of their immune reaction for any Omicron-specific vaccine upgrade.

"The advantage is that we have been practicing this pit stop for months and if we change tires for real we will be able to say we've demonstrated this before for one variant and for two variants," Sahin said.

He said he still expects a market launch with an initial batch of 25-50 million doses would take about 100 days, provided regulators are satisfied.

Sahin would not be drawn on whether Omicron will become as dominant as the Delta variant. "But even if, that in itself is no reason to panic," he said.

The EU drug regulator said on Tuesday it could approve vaccines adapted to target Omicron within three to four months if needed, but that existing shots would continue to provide protection.

(Reporting by Ludwig Burger and Patricia Weiss; Editing by Jan Harvey and Grant McCool)


ę Reuters 2021
All news about MODERNA, INC.
01/19Prior COVID infection more protective than vaccination during Delta surge, U.S. study f..
RE
01/19Valneva Shares Suffer as Coronavirus Vaccine Seen Arriving Too Late
DJ
01/18US Stocks Slump as Treasury Yields Hit 2-Year High, Goldman Sachs Weighs on Financials
MT
01/18US Stocks Start Week Lower as Treasury Yields Hit 2-Year High, Goldman Sachs Weighs on ..
MT
01/18Morgan Stanley Adjusts Moderna Price Target to $315 From $313, Maintains Equal Weight R..
MT
01/18Equities Slump Midday After Treasury Yields Touch Two-Year High, Goldman's Earnings Mis..
MT
01/18MIDDAY REPORT : US Stocks Slump After Treasury Yields Touch Two-Year High; Goldman's Earni..
MT
01/18EU regulator finds mRNA COVID-19 shots safe during pregnancy
RE
01/18European Medicines Agency Says mRNA COVID-19 Vaccines Safe In Pregnancy
MT
01/18EU regulator says mRNA COVID-19 shots do not complicate pregnancies
RE
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 17 520 M - -
Net income 2021 11 079 M - -
Net cash 2021 9 774 M - -
P/E ratio 2021 6,59x
Yield 2021 -
Capitalization 70 577 M 70 577 M -
EV / Sales 2021 3,47x
EV / Sales 2022 2,36x
Nbr of Employees 1 300
Free-Float 90,5%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 19
Last Close Price 174,07 $
Average target price 273,19 $
Spread / Average Target 56,9%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-31.46%75 661
LONZA GROUP AG-15.05%52 427
IQVIA HOLDINGS INC.-14.11%46 293
SEAGEN INC.-15.72%23 824
ICON PUBLIC LIMITED COMPANY-17.86%20 707
CELLTRION, INC.-15.66%18 630